Rauth AM - Search Results

1

A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system.

Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY. Wong HL, et al. Among authors: rauth am. J Pharmacol Exp Ther. 2006 Jun;317(3):1372-81. doi: 10.1124/jpet.106.101154. Epub 2006 Mar 17. J Pharmacol Exp Ther. 2006. PMID: 16547167

2

Delivery of an anticancer drug and a chemosensitizer to murine breast sarcoma by intratumoral injection of sulfopropyl dextran microspheres.

Liu Z, Ballinger JR, Rauth AM, Bendayan R, Wu XY. Liu Z, et al. Among authors: rauth am. J Pharm Pharmacol. 2003 Aug;55(8):1063-73. doi: 10.1211/0022357021567. J Pharm Pharmacol. 2003. PMID: 12956895

3

In vitro toxicity to breast cancer cells of microsphere-delivered mitomycin C and its combination with doxorubicin.

Cheung RY, Rauth AM, Ronaldson PT, Bendayan R, Wu XY. Cheung RY, et al. Among authors: rauth am. Eur J Pharm Biopharm. 2006 Apr;62(3):321-31. doi: 10.1016/j.ejpb.2005.09.011. Epub 2005 Dec 5. Eur J Pharm Biopharm. 2006. PMID: 16330194

4

A new polymer-lipid hybrid nanoparticle system increases cytotoxicity of doxorubicin against multidrug-resistant human breast cancer cells.

Wong HL, Rauth AM, Bendayan R, Manias JL, Ramaswamy M, Liu Z, Erhan SZ, Wu XY. Wong HL, et al. Among authors: rauth am. Pharm Res. 2006 Jul;23(7):1574-85. doi: 10.1007/s11095-006-0282-x. Epub 2006 Jun 24. Pharm Res. 2006. PMID: 16786442

5

Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles.

Wong HL, Bendayan R, Rauth AM, Li Y, Wu XY. Wong HL, et al. Among authors: rauth am. Adv Drug Deliv Rev. 2007 Jul 10;59(6):491-504. doi: 10.1016/j.addr.2007.04.008. Epub 2007 May 1. Adv Drug Deliv Rev. 2007. PMID: 17532091 Review.

6

On the synergistic effect of doxorubicin and mitomycin C against breast cancer cells.

Shuhendler AJ, O'Brien PJ, Rauth AM, Wu XY. Shuhendler AJ, et al. Among authors: rauth am. Drug Metabol Drug Interact. 2007;22(4):201-33. doi: 10.1515/dmdi.2007.22.4.201. Drug Metabol Drug Interact. 2007. PMID: 18447000

7

A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells.

Shuhendler AJ, Cheung RY, Manias J, Connor A, Rauth AM, Wu XY. Shuhendler AJ, et al. Among authors: rauth am. Breast Cancer Res Treat. 2010 Jan;119(2):255-69. doi: 10.1007/s10549-008-0271-3. Epub 2009 Feb 17. Breast Cancer Res Treat. 2010. PMID: 19221875

8

Doxorubicin and mitomycin C co-loaded polymer-lipid hybrid nanoparticles inhibit growth of sensitive and multidrug resistant human mammary tumor xenografts.

Prasad P, Shuhendler A, Cai P, Rauth AM, Wu XY. Prasad P, et al. Among authors: rauth am. Cancer Lett. 2013 Jul 1;334(2):263-73. doi: 10.1016/j.canlet.2012.08.008. Epub 2012 Aug 15. Cancer Lett. 2013. PMID: 22902994

9

Cytotoxicity and mechanism of action of a new ROS-generating microsphere formulation for circumventing multidrug resistance in breast cancer cells.

Liu Q, Shuhendler A, Cheng J, Rauth AM, O'Brien P, Wu XY. Liu Q, et al. Among authors: rauth am. Breast Cancer Res Treat. 2010 Jun;121(2):323-33. doi: 10.1007/s10549-009-0473-3. Epub 2009 Jul 18. Breast Cancer Res Treat. 2010. PMID: 19618264

10

Characterization of a microsphere formulation containing glucose oxidase and its in vivo efficacy in a murine solid tumor model.

Liu Q, Rauth AM, Liu J, Babakhanian K, Wang X, Bendayan R, Wu XY. Liu Q, et al. Among authors: rauth am. Pharm Res. 2009 Oct;26(10):2343-57. doi: 10.1007/s11095-009-9951-x. Epub 2009 Aug 15. Pharm Res. 2009. PMID: 19685212

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

162 results

Search Page

Filters